Australia TGA ARTG recordAscyrus Medical Dissection Stent Hybrid Prosthesis - Aortic arch endovascular stent-graft
Australia TGA ARTG Registered Device · Cryolife Medical (Australia) Company Pty Ltd · Ascyrus Medical GmbH · Class III · Started May 24, 2023
Good Name: Cryolife Medical (Australia) Company Pty Ltd - Ascyrus Medical Dissection Stent Hybrid Prosthesis - Aortic arch endovascular stent-graft
- Risk Class
- Class III
- Product Type
- Single Device Product
- ARTG Category
- General
- Start Date
- May 24, 2023
- Effective Date
- May 24, 2023
- Country
- Germany
- Address
- Grosse Gallusstrasse 16-18, Frankfurt am Main, 60312
The AMDS is intended for aortic repair, aortic remodeling and re-expansion of the intimal flap within the ascending aorta, aortic arch, and into the descending aorta for patients with acute DeBakey Type I aortic dissections undergoing open surgical repair within 0-14 days of diagnosis.
Access comprehensive regulatory information for Ascyrus Medical Dissection Stent Hybrid Prosthesis - Aortic arch endovascular stent-graft in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is sponsored by Cryolife Medical (Australia) Company Pty Ltd, manufactured by Ascyrus Medical GmbH in Germany. The device registration started on May 24, 2023.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.